Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Purpose
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. A side effect is anything a medicine does to your body that is not part of how the medicine treats disease. - This study is seeking for participants who: Are willing to take all the required eye tests - Have not received TIVDAK before - Do not have any active eye issues. Participants will receive TIVDAK once every 3 weeks as an infusion that will be injected into the vein. Participants will visit an eye care provider at 3 stages: - before starting the treatment, - before each of the first 9 infusions - then monthly for 3 months after they stop taking TIVDAK. Treatment with TIVDAK will continue until it is not working anymore against the participant's cancer.
Condition
- Cervical Cancer
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Must have recurrent or metastatic cervical cancer with disease progression on or after chemotherapy 2. Treating physician has determined that treatment with Tivdak is appropriate for the participant according to US Prescribing Information 3. Must sign an informed consent form indicating that the participant understands the purpose and procedures required for the study and are willing to participate 4. Must be willing to undergo repeated ocular assessments as required by the study and regular clinic visits according to local standard practice of the study site 5. Must agree to use effective contraception according to the US Prescribing Information
Exclusion Criteria
- Active ocular disease at baseline per investigator assessment 2. Previous treatment with Tivdak 3. Previous administration of an investigational drug within 30 days 4. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may, in the investigator'
Study Design
- Phase
- Phase 4
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Other
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Tisotumab vedotin |
Participants will receive tisotumab vedotin by IV infusion. |
|
Recruiting Locations
Phoenix, Arizona 85016
Phoenix, Arizona 85016
Phoenix, Arizona 85034
Phoenix, Arizona 85258
Scottsdale, Arizona 85260
Scottsdale, Arizona 85260
Tempe, Arizona 85284
Aventura, Florida 33180
Bonita Springs, Florida 34135
Bradenton, Florida 34211
Cape Coral, Florida 33909
Coral Springs, Florida 33065
Daytona Beach, Florida 32117
Deerfield Beach, Florida 33064
Fleming Island, Florida 32003
Fort Lauderdale, Florida 33308
Fort Lauderdale, Florida 33316
Fort Myers, Florida 33905
Fort Myers, Florida 33908
Miami, Florida 33133
Miami Beach, Florida 33140
Miami Beach, Florida 33140
N. Venice, Florida 34275
Naples, Florida 34102
Orlando, Florida 32806
Orlando, Florida 32806
Orlando, Florida 32806
Port Charlotte, Florida 33980
Sarasota, Florida 34236
Stuart, Florida 34994
Wellington, Florida 33414
West Palm Beach, Florida 33401
Atlanta, Georgia 30303
Atlanta, Georgia 30303
Atlanta, Georgia 30308
Atlanta, Georgia 30322
Atlanta, Georgia 30322
Atlanta, Georgia 30322
Augusta, Georgia 30912
Chicago, Illinois 60607
Chicago, Illinois 60612
Peoria, Illinois 61615
Peoria, Illinois 61637
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
Louisville, Kentucky 40202
Louisville, Kentucky 40202
Louisville, Kentucky 40207
Louisville, Kentucky 40207
New Orleans, Louisiana 70112
Shreveport, Louisiana 71103
Shreveport, Louisiana 71103
Shreveport, Louisiana 71103
Shreveport, Louisiana 71103
Shreveport, Louisiana 71103
Shreveport, Louisiana 71118
Burnsville, Minnesota 55337
Edina, Minnesota 55435
Maple Grove, Minnesota 55369
Maplewood, Minnesota 55109
Minneapolis, Minnesota 55455
Woodbury, Minnesota 55125
Jackson, Mississippi 39216
Jackson, Mississippi 39216
Billings, Montana 59101
Billings, Montana 59102
Billings, Montana 59102
Billings, Montana 59106
Las Vegas, Nevada 89106
Camden, New Jersey 08103
Voorhees Township, New Jersey 08043
Brooklyn, New York 11220
Centerville, Ohio 45459
Kettering, Ohio 45429
Kettering, Ohio 45429
Tulsa, Oklahoma 74146
Providence, Rhode Island 02905
Providence, Rhode Island 02905
Austin, Texas 78731
Austin, Texas 78745
Austin, Texas 78758
Harlingen, Texas 78550
McAllen, Texas 78503
Waco, Texas 76712
Weslaco, Texas 78596
Charlottesville, Virginia 22903
Charlottesville, Virginia 22908
Charlottesville, Virginia 22911
Roanoke, Virginia 24016
San Juan, Puerto Rico 00917-5027
More Details
- Status
- Recruiting
- Sponsor
- Pfizer